Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 9/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2615701 | 1.00 | IDH1 (0.43) | IDH1ALDH1A1ATMCHRNB2CHRNB4 | |
| SCHEMBL5286742 | 1.00 | IDH1 (0.43) | IDH1ALDH1A1ATMCHRNB2CHRNB4 | |
| SCHEMBL3652984 | 0.82 | CHRNA7 (0.43) | ALDH1A1CHRNA7 | |
| SCHEMBL6903965 | 0.82 | CYP19A1 (0.39) | — | |
| SCHEMBL3652982 | 0.82 | CHRNA7 (0.43) | ALDH1A1CHRNA7 | |
| SCHEMBL3654550 | 0.82 | CHRNA7 (0.43) | ALDH1A1CHRNA7 | |
| SCHEMBL16181385 | 0.80 | CYP19A1 (0.45) | ALDH1A1 | |
| SCHEMBL2235912 | 0.80 | DDB1 (0.38) | — | |
| SCHEMBL2235902 | 0.80 | DDB1 (0.38) | — | |
| SCHEMBL6904113 | 0.80 | KDM4E (0.58) | IDH1ALDH1A1CHRNB2CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | claimed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | claimed |
| EP-0859766-B1 | CHIRAL METHYL PHENYL OXAZOLIDINONES | SCHERING AG (DE) | 2001-05-16 | — | — | EP | claimed |
| US-6025376-A | INHIBITORS OF TUMOR NECROSIS FACTOR, TREATING MULTIPLE SCLEROSIS | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-02-15 | — | — | US | claimed |
| WO-2018032356-A1 | PROCESS FOR PREPARATION OF LACTONE DERIVATIVES AND INTERMEDIATES THEREOF | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2018-02-22 | — | — | WO | disclosed |
| US-20170204065-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | ALCON INC. (CH) | 2017-07-20 | — | — | US | disclosed |
| US-20170137384-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | ALCON INC. (CH) | 2017-05-18 | — | — | US | disclosed |
| US-9643927-B1 | Process for the preparation of kinase inhibitors and intermediates thereof | AERIE PHARMACEUTICALS, INC. (US) | 2017-05-09 | — | — | US | disclosed |
| US-8703963-B2 | Derivative N-thiolated 2-oxazolidinone antibiotics | UNIVERSITY OF SOUTH FLORIDA (US) | 2014-04-22 | — | — | US | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-8354401-B2 | Oxazolidinone amide aromatic compounds for supressing MMP-9 production | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2013-01-15 | — | — | US | disclosed |
| US-20120149911-A1 | DERIVATIVE N-THIOLATED 2-OXAZOLIDINONE ANTIBIOTICS | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-06-14 | — | — | US | disclosed |
| WO-1997015561-A1 | CHIRAL METHYL PHENYL OXAZOLIDINONES | SCHERING AKTIENGESELLSCHAFT (DE) | 1997-05-01 | — | — | WO | disclosed |
| US-5461162-A | Reacting an (oxa- or thia)zolidone or a sultam with an anhydride in the presence of a lithium salt and an amine | MERCK & CO., INC. (US) | 1995-10-24 | — | — | US | disclosed |
| US-5449778-A | Peptide intermediates | WARNER-LAMBERT COMPANY (US) | 1995-09-12 | — | — | US | disclosed |
| EP-0637305-A1 | NOVEL CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1995-02-08 | — | — | EP | disclosed |
| US-5380925-A | Cyclic amino acids and derivatives thereof | WARNER-LAMBERT COMPANY (US) | 1995-01-10 | — | — | US | disclosed |
| US-5264577-A | Cyclic amino acids and derivatives thereof | WARNER-LAMBERT COMPANY (US) | 1993-11-23 | — | — | US | disclosed |
| WO-1993021176-A1 | NOVEL CYCLIC AMINO ACIDS AND DERIVATIVES THEREOF | WARNER-LAMBERT COMPANY (US) | 1993-10-28 | — | — | WO | disclosed |
| CN-1076200-A | NEW DERIVATIVES OF BETA-AMINO ACIDS | SANDOZ LTD (CH) | 1993-09-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137384-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | MAP3K1, MAP3K6, MAP3K7 | IDH1 440/4885ALDH1A1 2948/4885ATM 375/4885 |
| US-20120149911-A1 | DERIVATIVE N-THIOLATED 2-OXAZOLIDINONE ANTIBIOTICS | TST, NRDC, NUCB2 | IDH1 1637/4885ALDH1A1 1090/4885ATM 2954/4885 |
| US-20170204065-A1 | PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF | MAP3K1, MAP3K6, MAP3K7 | IDH1 440/4885ALDH1A1 2948/4885ATM 375/4885 |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | IDH1 4439/4885ALDH1A1 2972/4885ATM 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.